The Alzheimer's Impact Movement (AIM) is the advocacy arm of the Alzheimer's Association. AIM advances and develops policies to overcome Alzheimer's disease through increased investment in research, enhanced care and improved support. Thanks to the support of its members, AIM has driven policymakers to take historic steps to address the Alzheimer’s crisis — but much more remains to be done.
Today an estimated 5.7 million Americans are living with Alzheimer’s disease. And, at a cost of $277 billion a year, Alzheimer’s is the most expensive disease in the nation. Barring the development of medical breakthroughs to prevent, stop or slow Alzheimer’s disease, these numbers will rapidly increase.
It is because of this trajectory and the impact of the disease on families that AIM works to advance public policies to enhance care and support, as well as to accelerate research.
As a 501(c)(4), AIM is able to engage with lawmakers in all elements of their job — including activities considered electoral or political — to keep the Alzheimer’s community and our issues top-of-mind with elected officials.
AIM impresses upon our elected officials the growing crisis Alzheimer’s presents to our nation's families and the economy. In doing so, AIM is inspiring these leaders to take bold action to address Alzheimer’s.
AIM amplifies the voice of Alzheimer’s Association advocates — to lend them even more power. AIM carries this message to halls of Congress on behalf of the hundreds of thousands of Alzheimer’s advocates across the country.
Examples of what AIM can and has done include:
Thanks to the combined work of AIM and the Alzheimer’s Association, our community has celebrated historic advancements in Alzheimer’s public policy. Together, and with the tireless work of our advocates, we have:
Developed with Congress the National Alzheimer’s Project Act (NAPA), resulting in the first National Plan to Address Alzheimer’s Disease with the goal of preventing and effectively treating Alzheimer’s by 2025.
Created the concept of the Alzheimer’s Accountability Act (AAA). Once introduced, AIM and the Association were the only organizations to lobby in support of the bill which was enacted into law that same year. AAA and has transformed discussions about Alzheimer’s research funding on Capitol Hill.
Supported the 21st Century Cures Act to bolster medical research to accelerate the discovery, development and delivery of new treatments and cures for Alzheimer’s and other diseases.
Conceived of and championed the HOPE for Alzheimer’s Act to provide Medicare coverage for comprehensive care planning services for those living with Alzheimer’s disease and other cognitive impairments. Because of our efforts, congressional cosponsorship soared, and in November 2016, the Centers for Medicare & Medicaid Services (CMS) finalized a decision to pay for cognitive and functional assessments and care planning.
Worked with state governments to create State Alzheimer’s Plans in nearly every state.
Made Alzheimer’s a national priority on the 2016 campaign trail. Alzheimer’s became an issue at candidate debates, in candidate’s advertising, and for the first time in our nation’s history, an incoming president has declared Alzheimer’s disease would be a priority of his administration.
Supported and advocated for the RAISE Family Caregivers Act which requires the Department of Health and Human Services (HHS) to develop, maintain and periodically update a National Family Caregiving Strategy.
Worked to secure an extension of the Independence at Home (IAH) demonstration model through 2019. The IAH demonstration model provides Medicare beneficiaries with multiple, complex chronic conditions with specialized care at home from a team of healthcare providers.
Worked with House and Senate bipartisan champions to secure the largest increase in federal funding for Alzheimer’s research at the National Institutes of Health, for the third year in a row — a $414 million increase in fiscal year 2018.
Advocated for and secured the largest increase in federal funding for Alzheimer's research at the National Institutes of Health, for the fourth year in a row — a $425 million increase in fiscal year 2019.